China’s Hansoh Pharmaceutical is slated to go public in Hong Kong on Friday. The $1 billion raise puts it among the largest IPOs on the exchange this year. But perhaps what’s more interesting is how the market value will create one
read morePfizer’s troubled JAK inhibitor Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s higher dose in rheumatoid arthritis. Now, Pfizer is hoping for better results using Xeljanz to treat RA patients who wean off immunosuppressants.
read moreTwo new gene therapies—from Novartis and Spark—carry price tags higher than any other drugs in the U.S., elbowing aside the brands we’ve seen at the top for years, a GoodRx analysis shows. And with drugmakers doubling down in rare diseases,
read moreThis competition aims to honour those with exceptional talent within the medical and scientific industry, by offering a platform for candidates to share best practice and prove they’ve got the skills to be successful. More: Strive for success in the
read more© 1994 - 2026 B.M. Pharmaceuticals